These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32534978)

  • 21. Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study.
    Barakat E; Bibok A; Rishi A; Ahmed A; Frakes JM; Hoffe SE; Armaghani AJ; Soyano AE; Costa RLB; El-Haddad G; Choi J; Kis B
    Adv Radiat Oncol; 2022; 7(1):100838. PubMed ID: 35071835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis.
    Buettner S; Braat AJAT; Margonis GA; Brown DB; Taylor KB; Borgmann AJ; Kappadath SC; Mahvash A; IJzermans JNM; Weiss MJ; Lamarca A; Bell JK; Valle JW; Hagendoorn J; Koerkamp BG; Sze DY; Lam MGEH
    J Vasc Interv Radiol; 2020 Jul; 31(7):1035-1043.e2. PubMed ID: 32473757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
    Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
    J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study.
    Miller MD; Sze DY; Padia SA; Lewandowski RJ; Salem R; Mpofu P; Haste PM; Johnson MS
    J Vasc Interv Radiol; 2018 Jun; 29(6):867-873. PubMed ID: 29724518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.
    Bibok A; Mhaskar R; Jain R; Zhang J; Frakes J; Hoffe S; El-Haddad G; Parikh N; Ahmed A; Fishman MN; Choi J; Kis B
    Cardiovasc Intervent Radiol; 2021 Nov; 44(11):1755-1762. PubMed ID: 34312688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
    Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
    J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.
    Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Minor DR; Sze DY
    J Vasc Interv Radiol; 2012 Mar; 23(3):323-30.e1. PubMed ID: 22277275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
    Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
    World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer.
    Davisson NA; Bercu ZL; Friend SC; Paplomata E; Ermentrout RM; Newsome J; Majdalany BS; Kokabi N
    J Vasc Interv Radiol; 2020 Jun; 31(6):925-933. PubMed ID: 32307310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
    Tsai AL; Burke CT; Kennedy AS; Moore DT; Mauro MA; Dixon RD; Stavas JM; Bernard SA; Khandani AH; O'Neil BH
    J Vasc Interv Radiol; 2010 Sep; 21(9):1377-84. PubMed ID: 20691606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study.
    Cao C; Yan TD; Morris DL; Bester L
    Tumori; 2010; 96(6):955-8. PubMed ID: 21388058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histological changes in nontumoral liver secondary to radioembolization of hepatocellular carcinoma with yttrium 90-impregnated microspheres: report of two cases.
    Dhingra S; Schwartz M; Kim E; Mabel Ko H; Ward SC; Fiel MI; Thung SN
    Semin Liver Dis; 2014 Nov; 34(4):465-8. PubMed ID: 25369308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience.
    Triviño-Ibáñez EM; Pardo Moreno P; Ciampi Dopazo JJ; Ramos-Font C; Ruiz Villaverde G; González-Flores E; Navarro Vergara PF; Rashki M; Gómez-Río M; Rodríguez-Fernández A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):231-238. PubMed ID: 34454892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of Blood Pressure Changes in the Vascular Compartment When Using an Anti-Reflux Catheter during Chemoembolization versus Radioembolization: A Retrospective Case Series.
    Rose SC; Narsinh KH; Newton IG
    J Vasc Interv Radiol; 2017 Jan; 28(1):103-110. PubMed ID: 27840042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres.
    Villalobos A; Arndt L; Cheng B; Dabbous H; Loya M; Majdalany B; Bercu Z; Kokabi N
    J Vasc Interv Radiol; 2023 Jul; 34(7):1226-1234. PubMed ID: 36958669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.
    Gordon AC; Gradishar WJ; Kaklamani VG; Thuluvath AJ; Ryu RK; Sato KT; Gates VL; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2014 Oct; 25(10):1523-32, 1532.e1-2. PubMed ID: 25156827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
    Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
    J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.